Treatment with a small molecule that blocks a key step in that pathway – the alternative lengthening of telomeres (ALT) pathway – was able to inhibit the growth and survival of ALT-positive tumor cells.
“Identification of genetic markers that predict cancer cell vulnerabilities and new drugs to exploit such vulnerabilities is a focal point of cancer research today,” says Lee Zou, PhD, associate scientific director of the MGH Cancer Center, senior and co-corresponding author of the report in the Jan. 16 issue of Science. “Cancer cells must rely on either the telomerase enzyme or the ALT pathway to bypass the normal processes of cell aging and death. Our findings may provide a new direction for the treatment of ALT-positive cancers – which include osteosarcoma, glioblastoma and certain pancreatic tumors.”
Telomeres are repetitive DNA sequences that sit at the ends of chromosomes and serve a protective function to make sure cells do not lose valuable genetic information each time they divide. When telomeres have been eroded to a critically short length, they send out a signal to the cell telling it to stop dividing, ensuring that the genetic information remains intact but limiting the cell’s lifespan. Cancer cells have evolved to overcome this constant attrition by continuously extending those eroded telomeres, promoting cellular immortality.
There are two major pathways for telomere elongation in cancer cells. The more common pathway relies on the enzyme telomerase to extend telomeres. The less understood ALT pathway lengthens telomeres through recombination with DNA sequences from other chromosomes.
In their investigations, the researchers studied how the action and expression of several key proteins is altered in cancer cells that use the ALT pathway. Focusing on a protein called ATR, a master regulator of DNA repair and recombination, the investigators verified that the protein also plays a crucial role in regulating the ALT pathway. They found that the ATR inhibitors VE-821 and AZ20 selectively eliminated ALT-positive osteosarcoma and glioblastoma cells from panels of cancer cell lines, suppressing their ability to extend their telomeres though recombination and leading to the cells’ death.
Co-corresponding and lead author Rachel Flynn, PhD, assistant professor of Pharmacology & Experimental Therapeutics and Medicine at BUSM, explains, “This study suggests that inhibiting ATR may be a novel and important strategy in treating cancers that rely on the ALT pathway, including up to 60 percent of osteosarcomas and 40 to 60 percent of glioblastomas. Such targeted treatments would only affect cancer cells and have little effect on the surrounding healthy tissue, potentially minimizing the harsh and debilitating side effects experienced with traditional cancer therapies.” Flynn began the project as a postdoctoral fellow in Zou’s MGH Cancer Center lab and completed the investigation after joining the faculty at BUSM.
While clinical trials of telomerase inhibitors for the treatment of cancer are currently underway, the up to 10 percent of tumors that do not use the telomerase pathway would not respond to such drugs. “Testing tumors for their use of telomerase or the ALT pathway is not yet routine,” Flynn says. “If VE-821 or other ATR inhibitors are clinically successful, it would support such testing and may lead to more personalized and targeted therapeutic regimens for several cancers refractory to traditional chemotherapeutics.”
In addition to Zou, who is a professor of Pathology at Harvard Medical School, co-authors of the Science article include Daniel Haber, MD, PhD, and Cyril Benes, PhD, of the MGH Cancer Center and Neil J. Ganem PhD an assistant professor in Pharmacology & Experimental Therapeutics at BUSM. Funding for the study includes Wellcome Trust grant 102696 and National Institute of Health grants GM076388 and CA166729. Flynn is supported by the Karin Grunebaum Cancer Research Foundation and the Foster Foundation, and Zou is a Jim and Ann Orr Massachusetts General Hospital Research Scholar and a senior scholar of the Ellison Medical Foundation.
Originally established in 1848 as the New England Female Medical College, and incorporated into Boston University in 1873, Boston University School of Medicine today is a leading academic medical center with an enrollment of more than 700 medical students and 800 students pursuing degrees in graduate medical sciences. Its 1,246 full and part-time faculty members generated more than $137.3 million in funding in FY2013 for research in amyloidosis, arthritis, cardiovascular disease, cancer, infectious diseases, pulmonary disease and dermatology, among others. The School’s teaching affiliates include Boston Medical Center, its primary teaching hospital, the VA Healthcare System in Boston, Roger Williams Medical Center in Rhode Island, as well as Boston HealthNet, a network of 15 community health centers.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $785 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
Media Contacts: Katie Marquedant, 617 726-0337, [email protected]